Announcement PDF OTCQX Life Sciences Presentation Melbourne, Australia; 1 October 2015: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that as part of its OTCQX investor communications, a pre-recorded presentation by Chief Executive Officer Dr Jackie Fairley will be broadcast at VirtualInvestorConferences.com on Thursday, October 1, 2015 at 12.15pm (EDT time). The presentation is part of a special OTCQX Life Sciences virtual Conference. The presentation will provide an overview of the Company for new investors including recent announcements:   EU marketing approval for VivaGel® BV; and Drug delivery license with AstraZeneca for DEP™ technology. Interested parties are able to register at www.virtualinvestorconferences.com or at the following link: http://tinyurl.com/101pre . An on-demand archive will be available for 90 days at www.virtualinvestorconferences.com. A copy of the presentation slides is attached. Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications. Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has three core development programs: VivaGel® portfolio, DEP™ drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships. Starpharma’s lead products are based on VivaGel® (SPL7013, astodrimer sodium), a proprietary dendrimer which has antimicrobial properties. VivaGel® formulated as a water based gel and delivered vaginally now has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and is under clinical development for the prevention of recurrent BV. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries. Inc., (TSE: JP3192800005) to market a value-added, VivaGel® condom. The VivaGel® condom is available for purchase in Australia under Ansell’s Lifestyles® Dual Protect™ brand. Ansell manufactures and sells leading condom brands worldwide, including LifeStyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, which is the world’s second largest condom market. In the wider pharmaceutical field, Starpharma has both partnered and internal programs in Drug Delivery. A number of dendrimerenhanced, or DEP® versions of existing drugs are under development. The most advanced of these is DEP® docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid tumours. In preclinical studies DEP® docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel). AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound, with potential for follow on compounds directed at a defined family of targets. In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama (formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®). For more information please visit: www.starpharma.com Media: Buchan Consulting Rebecca Wilson Mob: +61 417 382 391 rwilson@buchanwe.com.au Starpharma: Dr Jackie Fairley, CEO Nigel Baade, CFO and Company Secretary +61 3 8532 2704 investor.relations@starpharma.com Forward Looking Statements This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Page 2 of 2 Dr. Jackie Fairley CEO STARPHARMA HOLDINGS LIMITED ASX:SPL; OTCQX:SPHRY Corporate Overview September/October 2015 This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. 2 One of Australia’s most innovative technology companies • ASX 300 company (ASX:SPL) and US (OTCQX:SPHRY). • A platform technology with multiple product opportunities across the pharmaceutical, life science and agrochemical industries. • De-risked business model: • Portfolio of products based on proprietary polymers (dendrimers) in various stages of development including one product on market, a product recently approved for market entry, and in late stage clinical trials; • Developing first-in-class (new) therapies through a highly experienced inhouse commercialization team; • Established commercial partnerships - with some of the world’s leading companies accelerates product development, shares development risk, and transfers development costs; • Multiple “shots on goal” due to the versatility and broad applicability of Starpharma’s technology. • Multiple commercial and product development catalysts expected within next 12 months. • Strong cash position: Cash balance of A$30.8M (June 2015) Starpharma headquarters in Melbourne, Australia 3 One of Australia’s most innovative biotechnology companies Starpharma’s portfolio is a mix of internal programs and external commercial partnerships Starpharma’s Dendrimer Platform >80 granted patents VivaGel® Portfolio VivaGel® Condom Bacterial vaginosis VivaGel® BV Symptomatic Relief BV DEP™ Drug Delivery DEP™ docetaxel Partner Delivery Programs Agrochemicals Priostar® Improved Agrochemicals ie. Glyphosate Partner Priostar® Programs DEP™ VivaGel® BV oxaliplatin BV (and others) Prevention & other undisclosed Top 10 Pharma companies >50% Top 10 Ag. companies 4 Starpharma’s Pharmaceutical Development Portfolio Res Antimicrobial / Antiviral (SPL7013) VivaGel® BV BV Symptomatic Relief VivaGel® BV BV Prevention of Recurrence PC PhI PhII PhIII Reg. Mkt VivaGel® Condom Drug Delivery Oncology (Internal) Partnered programmes Drug Delivery DEP™ docetaxel (various cancers) DEP™ oxaliplatin Drug Delivery Various Oncology DEP™ Drug Delivery - DEP™ Delivery – oncology, diabetes etc. Completed Planned 5 EU Marketing Approval granted for VivaGel® BV • VivaGel® BV gains EU approval for the treatment and rapid relief of BV • Allows for marketing in 28 EU countries & EFTA countries (population >260m women) • EU Approval will be used as the basis for obtaining marketing approvals for VivaGel® BV in other countries • Discussions regarding marketing rights for VivaGel® BV underway with a number of potential commercial partners • Current market for the management of BV and associated symptoms is estimated to be in excess of US$750 million globally.  “It was like gone almost overnight”  “I would definitely use it again.”  “The next day I noticed a huge difference.”  “I would use it….I will use it indefinitely…” VivaGel® Trial Participants VivaGel® BV is a unique topical vaginal gel. Its proprietary active is not absorbed and acts locally to suppress the pathogens that cause BV and the associated signs and symptoms. 6 Starpharma’s DEP™ delivery license with AstraZeneca (LON:AZN) • AZ licensed DEP™ drug delivery platform in the development and commercialisation of a novel, proprietary AZ oncology compound • SPL eligible to receive development, launch and sales milestones for the first AZ DEP™ product of USD$126 million (A$180m) (including a signature payment US$2m) • Licence provides for application of DEP™ to multiple AZ compounds directed at a defined family of targets • Each subsequent qualifying product successfully developed and commercialised could yield USD$93m (A$133m) in milestone payments • Tiered royalties on net sales • AZ will fund all development and commercialisation costs "We already have a long-standing and successful working “SPL estimates that each product successfully commercialised under this agreement could be worth around US$450m to Starpharma and, depending on the range of indications and degree of commercial success in the market, potentially significantly more” relationship with Starpharma. This license agreement will enable us to further harness the DEP™ technology and evaluate its potential across novel molecules within our oncology portfolio.’’ Dr Susan Galbraith, Head of the Oncology Innovative Medicines Unit at AstraZeneca 7 DEP™ Drug Delivery Starpharma’s DEP™ docetaxel: Multiple benefits • Docetaxel (Taxotere®) is a blockbuster chemotherapeutic • Docetaxel sales: US$3.1B(2012) • Docetaxel is used in major cancer types including breast, prostate and lung cancer • Starpharma’s patented DEP™ docetaxel is a nanoparticle formulation with multiple advantages compared to Taxotere® DEP™ docetaxel vs. Taxotere® 1. Elimination of major dose-limiting side effect (neutropenia) 2. Detergent-free formulation (less toxic) 3. Tumour-targeting (40-70x more) • DEP™ patents filed will offer coverage to 2032 4. Extended duration (half-life) • DEP™ docetaxel Phase 1 Trial in Australia progressing 5. Improved efficacy (breast, well; promising preliminary findings with very good ovarian, prostate) tolerability 9 DEP™ docetaxel preclinical findings: Multiple advantages - Better efficacy and less toxicity T1/2 and Targeting Safety Efficacy Patents filed will offer coverage to 2032 10 DEP™ docetaxel: Phase 1 Clinical Trial Encouraging initial clinical data • Underway at 4 Australian sites* ; Open label study - allowing progressive release of results • Estimated sample: 25-30 cancer patients (various solid tumours) Current Status • DEP™ docetaxel administered every 3-4 weeks (no steroid pre-treatment required) • Patients currently being enrolled in dose escalation phase • several dosed with multiple cycles (up to 6 cycles) • dose-level exceeds commonly used Taxotere® dose 75mg/m2 • > 2/3 recruitment Interim Findings: DEP™ docetaxel well tolerated with encouraging anticancer activity • No neutropenia (docetaxel DLT) observed so far (c.f Taxotere® where published data indicates severe neutropenia will be suffered by 75% of patients given 60mg/m2 ) • No alopecia/hair loss or vomiting reported • A sizable number of patients have exhibited efficacy signals/anticancer activity (one with pancreatic Ca. stable disease over > 20 weeks; prostate, lung, H&N) • Enhanced Pharmacokinetics demonstrated (longer half-life, higher AUC and lower Cmax) • Expansion phase to follow at MTD *Alfred, Austin Health/Olivia Newton John CC, Liverpool and Royal Brisbane & Women’s Hospital 11 DEP™ docetaxel Pharmacokinetics (PK) in humans cf. Taxotere®^ Enhanced PK in humans 1. Extended duration of exposure with DEP™ docetaxel • DEP™ docetaxel plasma half-life substantially longer (~8 x) than Taxotere® (~150x longer in the initial, rapid phases of plasma clearance) 2. Increased extent of exposure with DEP™ docetaxel • DEP™ docetaxel drug exposure or Area Under the Curve (AUC) for total docetaxel, ~500-800x greater than an equivalent dose of docetaxel administered as Taxotere® • reflects the gradual release of docetaxel (DEP™ docetaxel acts as a ‘depot’ of docetaxel ) 3. Reduced peak drug levels with DEP™ docetaxel • Cmax (peak blood level) of docetaxel is substantially (~50100 times) lower for DEP™ docetaxel than Cmax of an equivalent dose of docetaxel administered as Taxotere® Example plasma drug levels over time DEP™ docetaxel vs.Taxotere®) ^ Taxotere® parameters based on published data (Bruno et al, 1996) 12 DEP™ docetaxel compared with BIND’s docetaxel Compelling product benefits for DEP™ DEP™ docetaxel Starpharma Benefit Manufacture complex, self assembled particles; potential for inconsistency b/w batches Standard chemistry SPL dendrimer manufacture readily scalable and validated through extensive FDA input Stability self loading particle; inherently unstable Excellent stability Important for drug approval, storage and subsequent shelf life Drug loading w/w 10% 25% SPL delivers higher dose per mg of drug 10-15nm Smaller particles enter tissues more easily Aspect BIND^ ^ Particle Size 60-120nm Tumour concentration of active 10-20x 30-60x Higher level of docetaxel delivery to tumour SPL - better efficacy & reduced toxicity Plasma Half life 6-20 hours >50 hours Longer duration of effect, less frequent dosing and greater anti cancer effect Water soluble (detergent free) No Yes; solubility ~ 20,000 fold increased Water soluble; detergent free (see below) Neutropenia prevented No Yes Avoids risks & need for expensive rescue therapies / GCSF and hospitalisation Polysorbate used Yes - cortisone pre-treatment required No - cortisone pre-treatment is not required Avoids potentially fatal toxicities with polysorbate-containing formulations ^ parameters based on published data 13 Additional DEP™ candidates • SPL’s dendrimer enhanced product (DEP™) nanoparticle technology  broad applicability, especially in oncology  allows for new patent filings creating proprietary products • Proof of DEP™ concept for docetaxel, doxorubicin, oxaliplatin, methotrexate, gemcitabine and paclitaxel, proteins (insulin), peptides and Targeted agents (ADCs) • A number of additional DEP™ candidates from the list below are currently in preclinical testing 2014 Sales / Peak Sales prior to loss of exclusivity (US$ M) Brand Generic Name Type of Drug Innovator Company Taxotere Docetaxel Cytotoxic Sanofi Aventis 3,036 Alimta Pemetrexed Anti-metabolite Eli Lilly 2,792 Eloxatin Oxaliplatin Cytotoxic Sanofi Aventis 2,293 Gemzar Gemcitabine Anti-metabolite Eli Lilly 1,720 Camptosar Irinotecan Cytotoxic Pfizer 1,100 Jevtana Cabazitaxel Cytotoxic Sanofi Aventis 363 Kadcyla Ado-trastuzumab emtansine ADC Roche 624 Adcetris Brentuximab vedotin ADC Takeda 395 14 Targeted DEP™ Conjugates (TDCs) A new approach to drug conjugate design More than 20 ADC drug licensing deals in the past 5 years 50% of the top 10 products are antibodies with 2013 sales in excess of $US38B The top 3 oncology products are antibodies with combined sales of US$20B THE WORLD’S FIRST ANTI-VIRAL CONDOM VivaGel® Portfolio VivaGel® Condom – World’s first antiviral condom Lifestyles® DUAL PROTECT™ - Available in Australian retail outlets Extensive consumer research of the VivaGel® condom^: • Confirms strong interest and purchase intent (~90%) • Strong consumer interest across genders, ages and relationship status “I would buy this product right now if I could…..” “I like the idea of a condom doing more for us than just being a barrier….seems more reassuring to know it’s doing extra” “I would definitely buy this product without a shadow of a doubt…..” VivaGel® Condom Consumer Research “I think that this product is amazing…... This product is very special and interesting.” “I have rated this product a 5/5 as this is a major breakthrough in the condom market and for world health…” THE WORLD’S FIRST ANTIVIRAL CONDOM DUAL PROTECT™ with VivaGel® : lubricated with VivaGel® which has been shown to inactivate up to 99.9% HIV, HPV and HSV (Herpes) in laboratory studies VivaGel ® Condom Consumer Research ^ Formal research conducted in 1800 condom users across USA, Europe, Asia and Sth America 17 VivaGel® condom: A compelling and differentiated product • Condom coated with SPL’s patented antiviral lubricant (VivaGel®) • VivaGel® shown in laboratory studies to inactivate up to 99.9% HIV, HPV & Herpes • Licensed to Ansell and Okamoto (SPL receives royalties on sales) • Regulatory Certification received in Japan and Australia, NZ other filings in progress • Product selling in Australia under Lifestyles® Dual Protect™ brand • Extensive international consumer research indicates strong consumer interest • Branded global condom market: $1.1B • VivaGel® condom patents to 2027 Partner Market Position/Share • Okamoto Industries (listed on TSE) Major Brands No. 1 in Japan with ~60% Japanese market Skinless® (the 2nd largest condom mkt. Est. ~US$500M) • Ansell Limited ASX:ANN • 003® Total revenues >US$760M No. 2 globally for condom sales ~ 20% global share of branded condom market (~$1.1B) Lifestyles® SKYN® ZERO® Manix® 18 Bacterial Vaginosis and VivaGel® BV: Two product opportunities Bacterial Vaginosis: • the most common vaginal infection worldwide • ~29% women infected in US; up to 51% in some groups • Recurrent BV an issue in 50-60% of BV sufferers • Current therapies have low cure rates and nasty side effects • No approved products for Recurrent BV (R-BV) “It was like gone almost overnight” “I would definitely use it again.” “The next day I noticed a huge difference.” “I would use it….I will use it indefinitely…”  VivaGel® BV Trial Participants     Product Proposition: VivaGel® BV: • a non-antibiotic therapy • management of BV symptoms and • prevention of Recurrent BV • a selective antimicrobial effect for pathogens that cause BV • a local effect and is not systemically absorbed • Large market opportunity for both prevention of recurrent BV and BV Symptomatic Relief * Global Data, IMS, various Industry reports 19 Bacterial Vaginosis and VivaGel® BV: Two product opportunities Drivers of Value Significant Market Size BV Indications VivaGel® Prevention of BV Recurrence >US$1B (Chronic use) VivaGel® BV: Symptomatic Relief (Acute use: 7d) US$750-1B Competitive Advantages • • • • Unmet need No Approved Products Designed for long term use • Not absorbed • • • • • Rapid onset Good efficacy Not absorbed Non antibiotic Tolerability benefits Development and Commercial Progress • Phase 3 Trials Underway (SPA) • Late stage License • Partner engagement underway • Efficacy at 5-7 days and excellent symptomatic relief • EU approval granted, further submissions • Partner engagement underway 20 VivaGel® BV Treatment & Symptomatic Relief of BV • VivaGel® BV gains EU approval for the treatment and rapid relief of BV • Allows for marketing in 28 EU countries & EFTA countries (population >260m women) • EU Approval will be used as the basis for obtaining marketing approvals for VivaGel® BV in other countries • Discussions regarding marketing rights for VivaGel® BV underway with a number of potential commercial partners • Current market for the management of BV and associated symptoms is estimated to be in excess of US$750 million globally. Time to resolution of odour as reported by clinical trial patients VivaGel® BV is a unique topical vaginal gel. Its proprietary active is not absorbed and acts locally to suppress the pathogens that cause BV and the associated signs and symptoms.  “It was like gone almost overnight”  “I would definitely use it again.”  “The next day I noticed a huge difference.”  “I will use it indefinitely…” VivaGel® BV Trial Participants 21 VivaGel® BV : Treatment & Symptomatic Relief of BV Odour Resolution and time to resolution 80% ** ** 70% 7.00 * 50% Placebo 40% VivaGel® 30% 20% *p<0.05 10% ** p<0.001 0% SPL7013-013 SPL7013-015 Time to Resolution (Days) % resolution 60% 8.00 6.00 5.00 86% Placebo 4.00 VivaGel® 3.00 2.00 1.00 SPL7013-016 - VivaGel® - 3 Clinical trials In 3 separate randomised , placebo-controlled trials VivaGel® consistently provided a statistically significantly greater improvement in odour resolution as compared to placebo SPL7013-013 Time to resolution of odour, as reported by patients, showed that VivaGel® resolved odour in 1 day, compared to 7 days for placebo 22 BV Prevention of Recurrence Phase 3 Program Two double-blind, multi-centre, randomised trials SPA granted by FDA ~600 p per trial ~100 sites across USA, EU, Asia, Mexico PERIODIC STUDY VISITS “Enriched” R-BV population: Nugent Score 4-10 Primary Endpoint: Recurrence of BV at or by week 16 visit Oral Metronidazole 7 days BASELINE SCREENING 1% SPL7013 Gel 1:1 randomization WEEK 16 12-weeks follow-up Placebo Gel 16-WEEK TREATMENT PERIOD (DURING WHICH PRIMARY ENDPOINT IS MEASURED) Dosing regimen: 5g gel every second day at bedtime SPA granted by FDA on trial design (EMA agreement also gained) Phase 3 Trials progressing well 23 Agrochemicals The Opportunity for Starpharma’s Priostar® Dendrimers in Agrochemicals The Challenge for Agrochemical Companies • • • The cost and risk of registering new agrochemical actives to market is rising.  fewer new actives being developed (~70  30 between 2000 and 2012)  Agrochemical companies have more focus on creating new products with existing actives However most formulation components are available to all formulators Priostar® benefits for innovative crop protection formulations Better in the can: • Solubility enhancement Better in the field: • Increased efficacy • Increased loading • Modification of soil penetration • Formulation stability • Protection of Actives • Reduction/removal of solvents – “greener” formulations Challenge for agrochemical companies… Starpharma’s Patented Priostar® offers… How to create defendably differentiated products without new actives? Improved formulations with high barrier to entry for competitors, with or without new actives 25 Starpharma’s Priostar® Agrochemical Programs Partnered Priostar® Programs Internal Priostar® Programs • Commercial agreements with many of the leading global agrochemical companies including Adama ( #7 globally; 2014 sales: ~US$3.2B ) • SPL is also developing a small number of complete formulations of selected generic actives with enhanced characteristics • Several programs, including glyphosate, are underway with numerous field trials conducted through the year • Field trials conducted both domestically and internationally to address different regional weed populations for global coverage • Internal development candidates include (USD sales 2012): Recent partnerships Glyphosate ($4-5B) Improve efficacy Metolachlor ($605M) Improve efficacy • Several have now progressed to field trials, with positive interim results Deltamethrin ($340M) Improve efficacy/ remove solvent • Anticipate move towards product registration subject to continued positive results Propiconazole ($350M) Improve efficacy / Loading Imidacloprid Improve efficacy / Loading (>$1B) • Priostar® exclusivity offered in a region on a per active basis  multiple potential opportunities for revenue streams • Estimated value of partners share of market for actives under development: >US$5B 26 Priostar® Dendrimer Glyphosate Formulation – Field Trial Data More effective in hard-to-kill weeds than comparable marketed formulation • 100 Percentage of controlled weeds 90 80 Dendrimer Glyphosate Product Dendrimer product more effective in a number of hard-to-kill weeds than comparable marketed glyphosate product • 7 regulatory-compliant field trials have now been completed • Tested in 16 weed species in Australia and overseas Leading Glyphosate Product 70 60 50 Conclusion: Priostar® formulation performance has consistently exceeded marketed formulations in these field studies. 40 30 20 • Two key benefits identified with Priostar® formulation: 10 • 0 5 days after application 14 days after application 28 days after application Proposition: Priostar® offers a unique opportunity to develop value-added, IP-protected agrochemical formulations with less expense and risk than new cropprotection actives Better overall effectiveness Dendrimer formulation leaves only minimal number of weeds alive at end of study whereas the marketed product had > 30% survival. • Early feedback of effectiveness to grower 3 to 4 times as much “brownout” after 5 days than marketed product 27 Starpharma Holdings – Key Financials (A$) Strong financial position (Financial Year to 30 June) FY 2015 AUD $M FY 2014 AUD $M Total revenue and income 1.7 1.3 R&D Tax Incentive 3.5 4.2 Net loss after tax (19.0) (14.6) Cash outflow from operations (13.6) (9.8) 30.8 24.0 Key Financial Data Cash at 30 June 28 Expected Short-Medium Term News Flow VivaGel® Portfolio: • Regulatory approvals for BV Symptomatic Relief product • Commercialisation agreements for BV Symptomatic Relief product • Progress VivaGel® Phase 3 BV Prevention of Recurrence trials • Launches of VivaGel® condom, further approvals/geographic roll-out DEP™ Drug Delivery: • Further data/completion DEPTM docetaxel clinical trial (MTD, efficacy signals) • Partnered program announcements and new deals • Advance additional DEPTM candidates through preclinical and into clinic Priostar® Dendrimers in Agrochemicals: • Advance internal candidates eg. glyphosate (Roundup®) including regulatory-compliant field trials • Pre-registration activities to support commercialisation • Partnered program announcements eg. Licences from existing and new deals 29 For Further Information Dr Jackie Fairley, CEO +613 8532 2704 Investor.relations@starpharma.com Twitter: @Starpharma_ASX VivaGel® Drug Delivery Agrochemicals 30